发明名称 Fused azole-pyrimidine derivatives
摘要 The present invention relates to hovel fused azolepyrimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the present invention exhibit enhanced potency for phosphotidylinositol-3-kinase (PI3K) inhibition, especially for PI3K-gamma inhibition and can be used for the prophylaxis and treatment of diseases associated with PI3K and particularly with PI3K-gamma activity. More specifically, the azole derivatives of the present invention are useful for treatment and prophylaxis of diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic diseases, chronic obstructive pulmonary disease (COPD), septic shock, joint diseases, autoixnmune pathologies such as rheumatoid arthritis, and Graves' disease, cancer, myocardial contractility disorders, heart failure, thromboembolism, ischemia, and atherosclerosis. The compounds of the present invention are also useful for pulmonary hypertension, renal failure, cardiac hypertrophy, as well as neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, diabetes and focal ischemia, since the diseases also relate to PI3K activity in a human or animal subject.
申请公布号 US7511041(B2) 申请公布日期 2009.03.31
申请号 US20050527376 申请日期 2005.10.14
申请人 BAYER PHARMACEUTICALS CORPORATION 发明人 SHIMADA MITSUYUKI;MURATA TOSHIKI;FUCHIKAMI KINJI;TSUJISHITA HIDEKI;OMORI NAOKI;KATO ISSEI;MIURA MAMI;URBAHNS KLAUS;GANTNER FLORIAN;BACON KEVIN
分类号 A01N43/58;A01N43/60;A61K31/495;A61K31/50;A61P29/00;C07D237/26;C07D237/36;C07D239/00;C07D241/36;C07D401/04;C07D471/00;C07D471/04;C07D471/14;C07D487/00;C07D487/04;C07D487/06;C07D491/00;C07D495/00;C07D497/00;C07D519/00 主分类号 A01N43/58
代理机构 代理人
主权项
地址